Activity of cladribine combined with etoposide in heavily pretreated patients with indolent lymphoid malignancies

Chemotherapy

Volumn 51, Issue 5, 2005, Pages 247-251

  Robak, T ^a   Szmigielska Kaplon A ^a   Blonski J Z ^a   Kasznicki, M ^a   Chojnowski, K ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

2 CdA; Chronic lymphocytic leukemia; Cladribine; Combined therapy; Etoposide; Non Hodgkin's lymphoma; Purine nucleoside analogues

Indexed keywords

CLADRIBINE; ETOPOSIDE; FLUDARABINE; PENTOSTATIN; RITUXIMAB;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; FEMALE; HUMAN; INFECTION; LYMPHATIC SYSTEM TUMOR; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTOPENIA; TIME SERIES ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLADRIBINE; ETOPOSIDE; FEMALE; HUMANS; INFECTION; INFUSIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEUTROPENIA; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 23944519367     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087251     Document Type: Article

References (19)

1. Tallman MS, Heakimian D: Purine nucleoside analogs: Emerging roles in indolent lymphoproliferative disorders. Blood 1995;86:2463-2474.
2. Robak T, Kasznicki M: Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia. Leukemia 2002;16:1015-1027.
3. Johnson SA, Thomas W: Therapeutic potential of purine analogue combinations in the treatment of lymphoid malignancies. Hematol Oncol 2000;18:141-153.
4. Robak T, Góra-Tybor J, Lech-Marańda E, Błoń ski JZ, Kasznicki M: Cladribine in combination with mitoxantrone and cyclophosphamide (CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies. Eur J Haematol 2001;66:188-194.
5. Kirstensen J, Nygren P, Liliemark J, Fridborg H, Killander A, Simonsson B, Oberg G, Larsson R: Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia. Leukemia 1994;8:1712-1717.
6. Damaynthi Y, Lown JW: Podophyllotoxins: Current status and recent developments. Curr Med Chem 1998;5:205-252.
7. Öztürk MA, Barista I, Altundag MK, Türker A, Yalçin S, Çelik I, Güllü I, Güler N, Öizisk Y, Kars A, Kansu E, Baltali E, Tekuzman G: Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma: Results of a single-center study of 32 patients. Chemotherapy 2002;48:252-258.
8. Larsson R, Fridborg H, Liliemark J, Csoka K, Kristensen J, de la Torre M, Nygren P: In vitro activity of 2′-chlorodeoxyadenosine (CdA) in primary cultures of human haematological and solid tumours. Eur J Cancer 1994;30A:1022-1026.
9. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849.
10. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 1996;87:4990-4997.
11. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS: Clinical staging of chronic lymphocytic leukemia. Blood 1997;46:219-234.
12. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A. Hagenbeek A, Capanillas-Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999;17:1244-1253.
13. Duffy DR, Santner TJ: Confidence intervals binomial parameter based on multistage tests. Biometrics 1987;47:207-214.
14. Robak T, Góra-Tybor J, Krykowski E, Walewski JA, Borawska L, Ceglarek B, Durczyński T, Sikorska A, MichalakK, Urasiński I, Opalińska J, Dmoszyńska A, Adamczyk-Cioch MB, Kuratowska Z, Dwilewicz-Trojaczek J, Boguradzki P, Dereń M, Maj S, Grieb P: Activity of 2-chlorodeoxyadenosine (cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgin's lymphoma. Leuk Lymphoma 1997;26:99-105.
15. Robak T, Góra-Tybor J, Urbańska-Ryś H, Krykowski E: Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin's lymphoma. Leuk Lymphoma 1999;32: 359-363.
16. Robak T, Góra-Tybor J, Chojnowski K: Cladribine as monotherapy or combined with dexamethasone and idarubicin or mitoxantrone in previously treated patients with low-grade lymphoid malignancies. Haematologica 2000;85:215-216.
17. Morton J, Taylor K, Bunce I, Eliadis P, Rentoul A, Moore D, Kelly C, Wright S, Bashford J, Rodwell R, Mulligan S, Firkin F, Dodds A, Parkin J, Lowenthal R, Kimber R, Frost T, Grigg A, Goldstein D, Stone J, Lee N: High response rates with short infusional 2-chlorodeoxyadenosine in de novo and relapsed low-grade lymphoma. Australian and New Zealand Lymphoma Study Group. Br J Haematol 1996;95:110-115.
18. Liliemark J, Porwit A, Juliusson G: Intermittent infusion of cladribine (CdA) in previously treated patients with low-grade non-Hodgkin's lymphoma. Leuk Lymphoma 1997;25:313-318.
19. Dogan AL, Dogan A, Canpinar H, Duzguncinar O, Demirpence E: Effect of fludarabine on leukocyte function. Chemotherapy 2004;50:283-288.